Micro Pharmaceuticals
Market Cap
₹1,547 ₹1,547 Cr.
P/E
34.03
PEG
2.10
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

The thesis comes alive if organic growth, medical-representative productivity and Equitas integration progress broadly on schedule, with hospital cross-selling adding to the core branded-pharma engine.

The bull path requires faster hospital cross-selling, stronger representative productivity and new-product conversion; the bear path reflects integration delays, weaker organic growth and productivity shortfalls.

Key Ratios

Debt to Equity
Debt to Equity
-
Div Yield (%)
Div Yield (%)
2.35
Individual < 2 lac
Individual < 2 lac
15.95 %
Institutions
Institutions
2.92 %
Market cap
Market cap
1,547 Cr
No. of Shareholders
No. of Shareholders
24,181
OPM (%)
OPM (%)
20.79 %
PE
PE
34.03
Prom Holding
Prom Holding
69.05 %
ROCE (%)
ROCE (%)
21.02
ROE (%)
ROE (%)
15.60
Sales
Sales
293 Cr
  • Jagsonpal Pharma
  • Bharat Parenterals
  • Lincoln Pharma
Last updated on 1 Oct 2026
  • Jagsonpal is an India-only branded generics drug maker focused on gynaecology, orthopaedics and dermatology. It outsources manufacturing and research.
  • It sells only branded drugs across India through its field force and distributors. It avoids government tenders.
  • It sold its Faridabad factory in FY25. It is shifting from high-volume acute drugs toward semi-chronic specialty brands.
  • Profit rests on pain drug Indocap and pregnancy-support drug Maintane and a few other core brands. The top ten drive about three-fifths of sales.
  • It ranks second in orthopaedics and seventh in gynaecology. Five of its brands rank first in their molecules. Fourteen rank in the top five.
  • It is broadening into hospital drugs and consumer wellness. It is integrating its hospital subsidiary Aequitas. It stays open to further price-disciplined acquisitions.
  • Revenue grew 9% in Q1FY27. EBITDA grew 21% at above 23% margin. The print broke the flat sales patch of the prior two quarters.
  • It remains net cash positive after large payouts.
  • Near-term profit depends on lifting field-force output and digesting two acquisitions. Management guides 12-15% FY27 revenue growth toward ₹500Cr by 2028.
  • One formulation customer brings 19% of revenue. A past lead brand collapsed when competition rose.
  • 12-15% growth guide test first half Nov 2026
    Q2 shows if growth stays on the 12-15% full-year path.
  • Bought wellness brands ramp Q3FY27
    The deal adds a ₹24.6Cr portfolio at ~78% gross margin to a ~₹287Cr base. Extra payment of up to ₹23Cr depends on FY28 sales.
  • Hospital subsidiary Aequitas ramp by Q3FY27
    Management guides ₹100Cr revenue and ₹10Cr EBITDA by FY28-29 from a ₹53Cr base.
  • FY27 new launches 1-2 per quarter
    Management targets over 3% of growth from new products.
  • Field-force output No timeline
    Progress shows if sales per person lifts toward the ₹3.5L monthly target.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
155
52W Range
High
265
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

13 Yes

Positive for this company

2 Neutral

Neutral for this company

2 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Peer Comparison

Corporate Actions

Consolidated
DATE
DETAILS
Show More
Show Less
Show More
Show Less

FAQs on Jagsonpal Pharmaceuticals Ltd. Business

Jagsonpal Pharmaceutical, founded in 1964, specializes in research, development, manufacturing, and distribution of bulk drugs and pharmaceutical formulations globally, aiming to establish a strong presence in the industry.

Jagsonpal Pharma major competitors are Bharat Parenterals, Lincoln Pharma, Anuh Pharma, Panacea Biotec, Syncom Formulations, Fredun Pharma, Kilitch Drugs(India).
Market Cap of Jagsonpal Pharma is ₹1,530 Crs.
While the median market cap of its peers are ₹1,184 Crs.

Jagsonpal Pharma seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Company Filing

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material